Title:
Antiviral options against SARS-CoV-2 infection
Authors:
Aleksandr Ianevski, Rouan Yao, Mona H. Fenstad, Svetlana Biza, Eva Zusinaite, Hilde Lysvand, Kirsti Loeseth, Veslemoy M. Lamndsem, Janne F. Malmring, Valentyn Oksenych, Sten E Erlandsen, Per Arne Aas, Lars Hagen, Caroline H. Pettersen, Jan Egil Afset, Svein Arne Nordbo, Magnar Bjoras, Denis E Kainov
Published:
bioRxiv, 12 May 2020
https://www.biorxiv.org/content/10.1101/2020.05.12.091165v1
[This article is a preprint. It has not been peer-reviewed.]
From the abstract:
"As of May 2020, the number of people infected with SARS-CoV-2 continues to skyrocket, with more than 4,3 million cases worldwide. Both the World Health Organization (WHO) and United Nations (UN) has highlighted the need for better control of SARS-CoV-2 infections. Developing novel virus-specific vaccines, monoclonal antibodies and antiviral drugs against SARS-CoV-2 can be time-consuming and costly. Convalescent plasma and safe-in-man broad-spectrum antivirals (BSAAs) are readily available treatment options. Here we developed a neutralization assay using SARS-CoV-2 virus and monkey Vero-E6 cells. We identified most potent sera from recovered patients for treatment of SARS-CoV-2-infected patients."